A Phase 4 interventional study of Roxadustat and rHuEPO in Anemia of Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 8 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-04-22.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing roxadustat in Renal Insufficiency, Chronic — none open to participants now, 1 under way, 1 of them phase 3. roxadustat · Renal Insufficiency, Chronic.
Among the 19 studies testing roxadustat in Renal Insufficiency, Chronic, this one is the 17th largest by enrollment, is the only one that started in 2021, is one of 2 in phase 4, and was the 16th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →None of the 19 studies testing roxadustat in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →
roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2021.
This study's enrollment of 25 is below the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 161 across the 19 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
54 studies in Renal Insufficiency, Chronic by AstraZeneca: 6 open now, 11 under way, 5 of them phase 3. Of 43 finished, 18 (42%) have results posted.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 29th largest by enrollment of the 38 interventional ones that give a count, is one of 8 that started in 2021, is one of 3 in phase 4, and was the 16th registered.
AstraZeneca’s Renal Insufficiency, Chronic studies by the year they started, since 2003.
1 of the studies testing roxadustat in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing roxadustat in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 54 in Renal Insufficiency, Chronic:
This tab as a report to print or save as PDF → With an account.
This is a Phase IV, randomized, active-controlled, open-label, parallel design, multicenter prospective study to evaluate the effect of roxadustat versus rHuEPO treatment on the gastrointestinal (GI) iron absorption in patients with anemia of Stage 4 and Stage 5 CKD.
This is an open-label study, after eligibility confirmation patients will be randomized in a 1:1 ratio to either roxadustat or rHuEPO arms for 2 weeks.
The study will enroll eligible dialysis and non-dialysis patients ≥18 years of age, who have anemia of CKD, and are either dialysis-dependent (DD) and on a stable dose of rHuEPO within 4 weeks prior to screening, or are non-dialysis-dependent (NDD) and are being treated with rHuEPO (ie, on a stable dose of rHuEPO within 4 weeks prior to screening), or are rHuEPO -naïve at the time of screening.
Each patient will be contacted before the first Screening Visit (Visit 1) for the symptoms of coronavirus disease of 2019 (COVID-19) and for any contact with COVID-19 positive person within the past 14 days.
For each patient, the duration of participation in the study will be approximately 8 to 9 weeks divided into 3 periods: Screening Period (approximately 2-3 weeks); Treatment Period (2 weeks) and Post-Treatment Follow-up Period (4 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
• Provision of signed and dated, written informed consent form (ICF) prior to any mandatory study specific procedures, sampling, and analyses.
Type of patient and disease characteristics
At Visit 1 prior to screening
Dialysis patients:
Non-dialysis patients:
Dialysis and non-dialysis patients:
At Visit 1 (screening)
During the Screening Period:
At Visit 1 Screening:
Reproduction:
Contraceptive methods must be practiced upon being randomized to the study and through 7 days after the last dose of study treatment. Male patients must not donate or bank sperm during this same time period.
Exclusion Criteria:
Medical conditions
Prior/concomitant therapy:
Prior/concurrent clinical study experience:
Other exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive oral dose of roxadustat three times a week (TIW) for 2- weeks during treatment period.
Drug: Roxadustat
Patients will receive uniform brand of short acting intravenous or subcutaneous dose of rHuEPO two times a week (BIW) or TIW based upon their previous dose of rHuEPO for 2- weeks during treatment period.
Drug: rHuEPO
The starting dose of roxadustat will be in accordance with the China package insert, and will depend on the body weight of the patient: 100 mg (45 to \< 60 kg) or 120 mg (≥ 60 kg) in patients on dialysis; 70 mg (40 to \< 60 kg) or 100 mg (≥ 60 kg) in non-dialysis patients.
The starting dose of rHuEPO will be in accordance to the dosage approved in rHuEPO China package insert (patients on weekly dose of 6000 IU \[dosing will BIW\], and patients on weekly dose of \>6000 IU \[dosing will TIW\]) and on patient's haemoglobin levels.
Difference From Baseline to Day 15 in Area Under Curve (AUC) of GI Iron Absorption (0-3 Hours)
The main effect of roxadustat versus rHuEPO on GI iron absorption was evaluated.
Time frame: From Baseline (Day 1) to Day 15
Difference From Baseline to Day 15 in Area Under Curve (AUC) of Iron Absorption (0-3 Hours)
The effect and interaction with key baseline variables of roxadustat versus rHuEPO on iron absorption was assessed.
Time frame: From Baseline (Day 1) to Day 15
Difference From Baseline to Day 15 in Serum Iron
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: serum iron was assessed.
Time frame: From baseline (Day 1) to Day 15
Difference From Baseline to Day 15 in Ferritin
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Ferritin was assessed.
Time frame: From baseline (Day 1) to Day 15
Difference From Baseline to Day 15 in Total Iron Binding Capacity (TIBC)
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TIBC was assessed.
Time frame: From baseline (Day 1) to Day 15
Relative Difference From Baseline to Day 15 in Transferrin Saturation (TSAT)
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TSAT (fraction of TIBC) was assessed.
Time frame: From baseline (Day 1) to Day 15
Difference From Baseline to Day 15 in Transferrin
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Transferrin was assessed.
Time frame: From baseline (Day 1) to Day 15
Difference From Baseline to Day 15 in Soluble Transferrin Receptor
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Soluble transferrin receptor was assessed.
Time frame: From baseline (Day 1) to Day 15
Difference From Baseline to Day 15 in Hepcidin
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of Hepcidin was assessed.
Time frame: From baseline (Day 1) to Day 15
Number of Subjects With Adverse Events (AEs)
AEs as variables of safety was assessed.
Time frame: From screening (Starting on Day -21) until follow up (28 days) (approximately 7 weeks)
The study was conducted in 25 subjects at 8 clinical sites in China, of which 5 sites enrolled patients from 17 March 2021 (first subject first randomized) to 12 October 2021 (last subject last visit).
| Milestone | Roxadustat | rHuEPO |
|---|---|---|
| Started | 13 | 12 |
| Completed | 12 | 12 |
| Not completed | 1 | 0 |
| Withdrew: Failure to meet inclusion/exclusion criteria/ due to covid-19 pandemic | 1 | 0 |
The main effect of roxadustat versus rHuEPO on GI iron absorption was evaluated.
| gram*3hours/deciliter (g*3hr/dL) | Roxadustat | rHuEPO |
|---|---|---|
| Change from baseline | 11.288 ± 28.1506 | -0.259 ± 9.7369 |
| Hemodialysis (HD) group- Change from baseline | 20.125 ± 29.9536 | -1.625 ± 10.2189 |
| Peritoneal dialysis (PD)- Change from baseline | -2.408 ± 19.4973 | -2.263 ± 6.7321 |
| Non-dialysis-dependent (NDD)- Change from baseline | 34.700 ± 39.8808 | 15.950 ± NA |
The effect and interaction with key baseline variables of roxadustat versus rHuEPO on iron absorption was assessed.
| gram*3hours/deciliter (g*3hr/dL) | Roxadustat | rHuEPO |
|---|---|---|
| Difference From Baseline to Day 15 in Area Under Curve (AUC) of Iron Absorption (0-3 Hours) | 11.288 ± 28.1506 | -0.259 ± 9.7369 |
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: serum iron was assessed.
| micromole/Liter (µmol/L) | Roxadustat | rHuEPO |
|---|---|---|
| Difference From Baseline to Day 15 in Serum Iron | 2.077 ± 7.9263 | -0.845 ± 7.6225 |
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Ferritin was assessed.
| microgram/Liter (µg/L) | Roxadustat | rHuEPO |
|---|---|---|
| Difference From Baseline to Day 15 in Ferritin | -49.354 ± 175.3039 | -43.536 ± 79.3449 |
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TIBC was assessed.
| micromole/Liter (µmol/L) | Roxadustat | rHuEPO |
|---|---|---|
| Difference From Baseline to Day 15 in Total Iron Binding Capacity (TIBC) | 8.638 ± 5.1118 | -0.490 ± 3.7784 |
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TSAT (fraction of TIBC) was assessed.
| Ratio | Roxadustat | rHuEPO |
|---|---|---|
| Relative Difference From Baseline to Day 15 in Transferrin Saturation (TSAT) | -0.024 ± 0.1806 | -0.030 ± 0.2007 |
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Transferrin was assessed.
| gram/Liter (g/L) | Roxadustat | rHuEPO |
|---|---|---|
| Difference From Baseline to Day 15 in Transferrin | 0.452 ± 0.3550 | -0.012 ± 0.1393 |
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Soluble transferrin receptor was assessed.
| milligram/Liter (mg/L) | Roxadustat | rHuEPO |
|---|---|---|
| Difference From Baseline to Day 15 in Soluble Transferrin Receptor | 1.876 ± 3.0627 | 0.466 ± 0.5556 |
The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of Hepcidin was assessed.
| microgram/Liter (µg/L) | Roxadustat | rHuEPO |
|---|---|---|
| Difference From Baseline to Day 15 in Hepcidin | -78.769 ± 87.9264 | -44.239 ± 88.2325 |
AEs as variables of safety was assessed.
| Participants | Roxadustat | rHuEPO |
|---|---|---|
| Any AE | 5 | 2 |
| Any AE with outcome of death | 0 | 0 |
| Any Serious Adverse event (SAE) (including events with outcome of death) | 0 | 0 |
| Any AE leading to discontinuation of study treatment | 0 | 0 |
| Any AE leading to dose interruption | 0 | 0 |
| Any AE leading to dose reduction | 0 | 0 |
| Any AE leading to dose escalation | 0 | 0 |
| Any AE leading to withdrawal from study | 0 | 0 |
| Any AE possibly related to study treatment | 1 | 0 |
Collected over From screening (Starting on Day -21) until follow up (28 days) (approximately 7 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roxadustat | 0/13 (0%) | 0/13 (0%) | 5/13 (38.5%) |
| rHuEPO | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Event | Roxadustat | rHuEPO |
|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 1/13 | 2/12 |
| Abdominal infectionInfections and infestations | 1/13 | 0/12 |
| HypermagnesaemiaMetabolism and nutrition disorders | 1/13 | 0/12 |
| SeizureNervous system disorders | 1/13 | 0/12 |
| Open angle glaucomaEye disorders | 1/13 | 0/12 |
| Back painMusculoskeletal and connective tissue disorders | 1/13 | 0/12 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/13 | 0/12 |
The Full analysis Set (FAS) was the primary efficacy analysis set and included all randomized patients who completed baseline (Day 1) measurements for any efficacy analysis.
| Age, Continuous(Years) | Roxadustat | rHuEPO | Total |
|---|---|---|---|
| Mean | 57.3 ± 12.09 | 52.8 ± 12.64 | 55.1 ± 12.32 |
| Age, Customized(Participants) | Roxadustat | rHuEPO | Total |
|---|---|---|---|
| ≥ 18 to < 50 years | 5 | 4 | 9 |
| ≥ 50 to < 65 years | 3 | 6 | 9 |
| ≥ 65 to < 75 years | 4 | 2 | 6 |
| ≥ 75 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Roxadustat | rHuEPO | Total |
|---|---|---|---|
| Female | 9 | 7 | 16 |
| Male | 4 | 5 | 9 |
| Race/Ethnicity, Customized(Participants) | Roxadustat | rHuEPO | Total |
|---|---|---|---|
| Asian | 13 | 12 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Feb 2021 to primary completion in Oct 2021, 7 months.
Results were first posted in Apr 2024, 2 years 6 months after primary completion.
Of 116 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat
Renal Insufficiency, Chronic →